4/11/2024 | DD | Sorrento Therapeutics’ plan of liquidation effective as of April 10
|
3/12/2024 | DD | Sorrento Therapeutics gets final approval of $5 million DIP facility
|
3/12/2024 | DD | Sorrento Therapeutics’ case to stay open in Texas, court rules
|
3/4/2024 | DD | Sorrento Therapeutics gets interim access to $5 million DIP facility
|
3/4/2024 | DD | Sorrento Therapeutics, Scilex reach settlement with Virpax
|
3/1/2024 | DD | Sorrento Therapeutics reports $5.07 million net loss for January
|
2/23/2024 | DD | Sorrento Therapeutics’ DIP motion draws U.S. trustee objection
|
2/20/2024 | DD | Sorrento Therapeutics eyes $5 million DIP facility with BioVintage
|
2/20/2024 | DD | Sorrento Therapeutics’ case should be moved or dismissed, trustee says
|
2/6/2024 | DD | Sorrento Therapeutics gets sixth extension of exclusive plan periods
|
1/9/2024 | DD | Sorrento Therapeutics seeks sixth extension of exclusive plan periods
|
12/19/2023 | DD | Sorrento Therapeutics gets fifth extension of exclusive plan periods
|
12/1/2023 | DD | Sorrento Therapeutics receives confirmation of plan of liquidation
|
11/27/2023 | DD | Sorrento Therapeutics seeks fifth extension of exclusive plan periods
|
11/17/2023 | DD | Sorrento Therapeutics plan hearing moved, voting results given
|
11/16/2023 | DD | Sorrento Therapeutics reports $100.7 million net profit for September
|
11/13/2023 | DD | Sorrento Therapeutics’ plan draws objection from equity committee
|
11/3/2023 | DD | Sorrento Therapeutics closes sale of ImmuneOncia shares to Yuhan
|
10/19/2023 | DD | Sorrento Therapeutics’ disclosure statement conditionally approved
|
10/13/2023 | DD | Sorrento Therapeutics seeks extension of exclusive plan periods
|
10/12/2023 | DD | Sorrento Therapeutics files Chapter 11 plan and disclosure statement
|
10/11/2023 | DD | Sorrento Therapeutics seeks approval to sell ImmuneOncia shares
|
10/5/2023 | DD | Sorrento Therapeutics gets third extension of exclusive plan periods
|
9/21/2023 | DD | Sorrento Therapeutics seeks exclusivity extension, closes Scilex stock sale
|
9/21/2023 | DD | Sorrento Therapeutics seeks extension of exclusive plan periods
|
9/13/2023 | DD | Sorrento Therapeutics gets OK to sell Scilex stock back to Scilex
|
9/11/2023 | DD | Sorrento Therapeutics pivots away from sale of Scilex stock to Oramed
|
9/1/2023 | DD | Sorrento gets more time to file plan under amended DIP order
|
8/28/2023 | DD | Sorrento Therapeutics receives court approval to sell Scilex stock
|
8/25/2023 | DD | Sorrento’s sale of Scilex stock to Oramed draws objection from Scilex
|
8/16/2023 | DD | Sorrento Therapeutics posts $64.24 million net loss for June
|
8/14/2023 | DD | Sorrento receives approval of Nant settlement, exclusivity extension
|
8/11/2023 | DD | Sorrento seeks exclusivity extension, subsidiary DIP lender objects
|
8/7/2023 | DD | Sorrento nixes Hundred Gain deal, lines up sale, financing via Oramed
|
7/28/2023 | DD | Sorrento gets final approval of $20 million DIP loan via subsidiary
|
7/25/2023 | DD | Sorrento lines up $200 million exit financing deal via Hundred Gain
|
7/21/2023 | DD | Sorrento, equity committee launch offering to Scilex dividend short holders
|
7/14/2023 | DD | Sorrento Therapeutics lender objects to proposed Scilex settlement
|
7/7/2023 | DD | Sorrento Therapeutics receives asked-for exclusivity extension
|
7/6/2023 | DD | Sorrento gets interim OK of $20 million DIP loan via subsidiary
|
7/3/2023 | DD | Sorrento seeks approval of $20 million junior DIP loan via subsidiary
|
6/15/2023 | DD | Sorrento Therapeutics records $13.27 million net loss for April
|
6/12/2023 | DD | Sorrento Therapeutics seeks 59-day exclusivity extension
|
6/8/2023 | DD | Sorrento settlement with Nant draws objection from DIP lender
|
6/7/2023 | DD | Sorrento Therapeutics reaches settlement with Nant via mediation
|
5/19/2023 | DD | Sorrento Therapeutics, Scintilla give operating results for March
|
5/2/2023 | DD | Sorrento Therapeutics records $14.89 million net loss for February
|
4/14/2023 | DD | Sorrento Therapeutics secures approval of three-prong bid procedures
|
4/11/2023 | DD | Sorrento Therapeutics seeks approval of three-prong bid procedures
|
3/30/2023 | DD | Sorrento Therapeutics to have official equity committee appointed
|
3/29/2023 | DD | Sorrento Therapeutics gets final approval of $75 million DIP loan
|
3/28/2023 | DD | Sorrento Therapeutics: Court kicks NantCell off creditors committee
|
3/24/2023 | DD | Sorrento unsecured creditors object to equity committee appointment
|
3/17/2023 | DD | Sorrento Therapeutics equity holders want official representation
|
3/17/2023 | DD | Sorrento Therapeutics wins $125 million arbitration award against NantPharma
|
3/16/2023 | DD | Sorrento Therapeutics: U.S. trustee says NantCell should stay on committee
|
3/13/2023 | DD | Sorrento Therapeutics asks court to remove NantCell from committee
|
2/23/2023 | DD | Sorrento Therapeutics asks bankruptcy court to appoint mediator
|
2/21/2023 | DD | Sorrento Therapeutics gets interim OK of $75 million DIP financing
|
2/21/2023 | DD | Sorrento Therapeutics seeks approval of $75 million DIP financing
|
2/17/2023 | BKCVDDEMHY | Prospect News reports five new defaults for Feb. 9-Feb. 15
|
2/16/2023 | DD | Sorrento Therapeutics gets approval of some first-day motions
|
2/13/2023 | DD | Sorrento Therapeutics files bankruptcy following legal disputes
|
9/30/2022 | PV | Sorrento gets $41.67 million bridge loan via B. Riley Commercial
|
9/29/2022 | LMPV | Sorrento’s Scilex unit buys back all senior secured notes due 2026
|
6/3/2022 | LMPV | Sorrento’s Scilex unit buys back $41.4 million senior secured notes
|
6/12/2020 | BKPV | Sorrento Therapeutics repays $120 million term loan with Oaktree
|
12/10/2019 | BKPV | Sorrento Therapeutics amends $120 million term loan with Oaktree
|
11/8/2018 | BKPV | Sorrento wraps $100 million five-year secured term loan with Oaktree
|
9/10/2018 | PV | New Issue: Sorrento unit settles $140 million private placement of notes due 2026
|
3/27/2018 | CV | Market Commentary: Landmark convertible preferreds on tap; Red Hat trades around parity; DISH active
|
3/27/2018 | CVPP | New Issue: Sorrento Therapeutics prices $120.5 million convertible notes to yield 5%, up 0.17%
|
3/24/2017 | BK | Sorrento pays down $20 million as part of loan agreement amendment
|
3/21/2017 | BK | Sorrento amendment extends availability of $10 million of term loan
|
11/28/2016 | BK | Sorrento gets $75 million term loan due 2020 via Hercules Capital
|
6/8/2016 | PP | Sorrento completes $140 million stock sale with $14 million tranche
|
6/6/2016 | PP | Sorrento completes $53.49 million of $150 million placement of stock
|
4/5/2016 | PP | Sorrento Therapeutics arranges $150 million private placement of stock
|
12/15/2014 | PP | Sorrento Therapeutics seals $41.69 million private placement of stock
|
6/13/2014 | PP | Sorrento greenshoe exercised for $28.77 million public sale of stock
|
5/15/2014 | PP | Sorrento prices $25.02 million public sale of common stock at $5.25
|
5/14/2014 | PP | Sorrento announces plans to price public offering of its common shares
|
10/25/2013 | PP | Sorrento greenshoe exercised for $34.6 million public sale of stock
|
10/23/2013 | PP | Sorrento reports plans to price public offering of its common shares
|
10/23/2013 | PP | Sorrento to price public offering of common shares with greenshoe
|
10/21/2013 | PP | Sorrento Therapeutics sells $1.85 million convertible promissory notes
|
3/14/2013 | PP | Sorrento Therapeutics wraps $6.42 million private placement of shares
|
5/14/2012 | PP | Sorrento Therapeutics lifts private placement of shares to $8 million
|
1/5/2012 | PP | Sorrento Therapeutics settles $2 million private placement of shares
|
12/23/2010 | PP | Sorrento Therapeutics wraps $3.6 million private placement of shares
|